Literature DB >> 21211502

Using HAQ-DI to estimate HUI-3 and EQ-5D utility values for patients with rheumatoid arthritis in Spain.

Agata Carreño1, Ignacio Fernández, Xavier Badia, Cristina Varela, Montserrat Roset.   

Abstract

BACKGROUND/
OBJECTIVE: Utility values are not usually assessed in clinical trials and do not allow cost-utility analysis to be performed with the data collected. The aim of this study was to derive relation functions so that Health Assessment Questionnaire - Disability Index (HAQ-DI) scores could be used to estimate Health Utilities Index - 3 (HUI-3) and EQ-5D utility values for patients with rheumatoid arthritis (RA).
METHODS: An observational, cross-sectional, naturalistic, multicentre study was conducted. A total of 244 patients aged 18 years or older, with RA according to American College of Rheumatology diagnostic criteria, were recruited. Sociodemographic and clinical variables were recorded and patients completed three generic HRQoL questionnaires: the HAQ-DI, the HUI-3, and the EQ-5D. Two linear regression models were used to predict HUI-3 and EQ-5D utility values as functions of HAQ-DI scores, age, and gender.
RESULTS: Patient mean age was 57.8 years old (standard deviation [SD], 13.3 years); 75.8% of the patients were women and 95.9% were white. Mean disease duration was 10.8 years (SD, 9 years). Patient distribution according to HAQ-DI severity was as follows: HAQ-DI < 0.5, 29%; 0.5 ≤ HAQ-DI < 1.1, 28%; 1.1 ≤ HAQ-DI < 1.6, 16%,1.6 ≤ HAQ-DI < 2.1, 15%; and HAQ-DI ≥ 2.1, 12%. HAQ-DI and EQ-5D mean scores were 1.02 (SD, 0.78) and 63.1 (SD, 20.3), respectively. Mean utility values for HUI-3 and time trade-off (TTO) were 0.75 (SD, 0.21) and 0.65 (SD, 0.3), respectively. The equations converting HAQ-DI scores to utilities were HUI-3 = 0.9527 - (0.2018 × HAQ-DI) +ε (R(2)=0.56), and TTO = 0.9567 - (0.309 × HAQ-DI) + ε (R(2)=0.54). Error distribution was non-normal. Age and gender were found to have no bearing on the utility functions.
CONCLUSIONS: HAQ-DI scores can be used to estimate HUI-3 and EQ-5D utility values for patients with RA in data obtained from studies where utility values have not been collected.
Copyright © 2011 International Society for Pharmacoeconomics and Outcomes Research (ISPOR). Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2011        PMID: 21211502     DOI: 10.1016/j.jval.2010.11.001

Source DB:  PubMed          Journal:  Value Health        ISSN: 1098-3015            Impact factor:   5.725


  11 in total

Review 1.  Evaluation of content on EQ-5D as compared to disease-specific utility measures.

Authors:  Fang-Ju Lin; Louise Longworth; A Simon Pickard
Journal:  Qual Life Res       Date:  2012-06-23       Impact factor: 4.147

2.  Mapping between HAQ-DI and EQ-5D-5L in a Chinese patient population.

Authors:  Thomas Patton; Hao Hu; Luan Luan; Keqin Yang; Shu-Chuen Li
Journal:  Qual Life Res       Date:  2018-07-04       Impact factor: 4.147

Review 3.  Rituximab as first choice for patients with refractory rheumatoid arthritis: cost-effectiveness analysis in Iran based on a systematic review and meta-analysis.

Authors:  Saeed Ahmadiani; Shekoufeh Nikfar; Somayeh Karimi; Ahmad Reza Jamshidi; Ali Akbari-Sari; Abbas Kebriaeezadeh
Journal:  Rheumatol Int       Date:  2016-04-30       Impact factor: 2.631

4.  Mapping health assessment questionnaire disability index (HAQ-DI) score, pain visual analog scale (VAS), and disease activity score in 28 joints (DAS28) onto the EuroQol-5D (EQ-5D) utility score with the KORean Observational study Network for Arthritis (KORONA) registry data.

Authors:  Hye-Lin Kim; Dam Kim; Eun Jin Jang; Min-Young Lee; Hyun Jin Song; Sun-Young Park; Soo-Kyung Cho; Yoon-Kyoung Sung; Chan-Bum Choi; Soyoung Won; So-Young Bang; Hoon-Suk Cha; Jung-Yoon Choe; Won Tae Chung; Seung-Jae Hong; Jae-Bum Jun; Jinseok Kim; Seong-Kyu Kim; Tae-Hwan Kim; Tae-Jong Kim; Eunmi Koh; Hwajeong Lee; Hye-Soon Lee; Jisoo Lee; Shin-Seok Lee; Sung Won Lee; Sung-Hoon Park; Seung-Cheol Shim; Dae-Hyun Yoo; Bo Young Yoon; Sang-Cheol Bae; Eui-Kyung Lee
Journal:  Rheumatol Int       Date:  2016-02-06       Impact factor: 2.631

5.  Area of Residence and Socioeconomic Factors Reduce Access to Biologics for Rheumatoid Arthritis Patients in Romania.

Authors:  Cătălin Codreanu; Claudiu C Popescu; Corina Mogoşan
Journal:  Biomed Res Int       Date:  2018-05-08       Impact factor: 3.411

6.  Cost-effectiveness analysis of treatment sequences containing tofacitinib for the treatment of rheumatoid arthritis in Spain.

Authors:  F Navarro; J M Martinez-Sesmero; A Balsa; C Peral; M Montoro; M Valderrama; S Gómez; F de Andrés-Nogales; M A Casado; Itziar Oyagüez
Journal:  Clin Rheumatol       Date:  2020-04-17       Impact factor: 2.980

7.  Health-related quality of life in patients with rheumatoid arthritis.

Authors:  Wanruchada Katchamart; Pongthorn Narongroeknawin; Wanwisa Chanapai; Phakhamon Thaweeratthakul
Journal:  BMC Rheumatol       Date:  2019-08-14

8.  A novel etanercept biosimilar Anbainuo plus methotrexate exhibits increased cost-effectiveness compared to conventional disease-modifying anti-rheumatic drugs in treating rheumatoid arthritis patients.

Authors:  Feng Tian; Jing-Yang Li; Zhen-Hua Wen; Xiao-Wen Luo; Li Deng; Liang Zhang; Jing-Yun He
Journal:  Medicine (Baltimore)       Date:  2019-11       Impact factor: 1.817

9.  Can Medical Cannabis Therapies be Cost-Effective in the Non-Surgical Management of Chronic Knee Pain?

Authors:  Christopher Vannabouathong; Meng Zhu; Yaping Chang; Mohit Bhandari
Journal:  Clin Med Insights Arthritis Musculoskelet Disord       Date:  2021-03-16

10.  Cost-effectiveness analysis of etanercept plus methotrexate vs triple therapy in treating Chinese rheumatoid arthritis patients.

Authors:  Zhi-Chao Shi; Hong-Ping Fei; Zhi-Liang Wang
Journal:  Medicine (Baltimore)       Date:  2020-01       Impact factor: 1.889

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.